Zevra Therapeutics (ZVRA) Projected to Post Quarterly Earnings on Tuesday

Zevra Therapeutics (NASDAQ:ZVRA) is expected to post its quarterly earnings results after the market closes on Tuesday, March 11th. Analysts expect Zevra Therapeutics to post earnings of ($0.39) per share and revenue of $8.93 million for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

Zevra Therapeutics Stock Up 0.6 %

ZVRA stock opened at $8.10 on Monday. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84. The business has a 50 day moving average price of $7.97 and a two-hundred day moving average price of $8.13. The company has a market cap of $432.35 million, a price-to-earnings ratio of -4.11 and a beta of 1.98. Zevra Therapeutics has a twelve month low of $4.20 and a twelve month high of $9.76.

Insider Transactions at Zevra Therapeutics

In other news, CFO R. Laduane Clifton sold 11,000 shares of Zevra Therapeutics stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $7.86, for a total transaction of $86,460.00. Following the completion of the transaction, the chief financial officer now directly owns 51,361 shares in the company, valued at approximately $403,697.46. The trade was a 17.64 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Joshua Schafer sold 10,500 shares of Zevra Therapeutics stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $7.86, for a total value of $82,530.00. Following the transaction, the executive vice president now owns 29,486 shares of the company’s stock, valued at $231,759.96. This represents a 26.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 85,773 shares of company stock worth $674,176. 2.40% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. Guggenheim set a $21.00 price target on Zevra Therapeutics and gave the company a “buy” rating in a research note on Tuesday, February 4th. Cantor Fitzgerald upgraded Zevra Therapeutics to a “strong-buy” rating in a research note on Wednesday, January 29th. Canaccord Genuity Group decreased their price target on Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a research note on Thursday, November 14th. Finally, HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Zevra Therapeutics in a research note on Wednesday, November 20th. Six investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, Zevra Therapeutics has an average rating of “Buy” and an average target price of $21.71.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.